Sign In
Buy SAUHF
Straumann Holding AG Earnings Calls
| Release date | Apr 29, 2026 |
| EPS estimate | $1.77 |
| EPS actual | $1.67 |
| EPS Surprise | -5.65% |
| Revenue estimate | 1.572B |
| Revenue actual | 1.586B |
| Revenue Surprise | 0.84% |
| Release date | Jun 30, 2025 |
| EPS estimate | $2.26 |
| EPS actual | $1.86 |
| EPS Surprise | -17.70% |
| Revenue estimate | 1.715B |
| Revenue actual | 1.697B |
| Revenue Surprise | -1.06% |
| Release date | Apr 11, 2025 |
| EPS estimate | - |
| EPS actual | - |
| Revenue estimate | - |
| Revenue actual | - |
| Release date | Dec 31, 2024 |
| EPS estimate | $1.52 |
| EPS actual | $1.09 |
| EPS Surprise | -28.29% |
| Revenue estimate | 1.35B |
| Revenue actual | 1.355B |
| Revenue Surprise | 0.339% |
Last 4 Quarters for Straumann Holding AG
Below you can see how SAUHF performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Dec 31, 2024 |
| Price on release | $122.52 |
| EPS estimate | $1.52 |
| EPS actual | $1.09 |
| EPS surprise | -28.29% |
| Date | Price |
|---|---|
| Dec 24, 2024 | $124.09 |
| Dec 26, 2024 | $124.57 |
| Dec 27, 2024 | $123.88 |
| Dec 30, 2024 | $123.35 |
| Dec 31, 2024 | $122.52 |
| Jan 02, 2025 | $121.91 |
| Jan 03, 2025 | $121.05 |
| Jan 06, 2025 | $124.47 |
| Jan 07, 2025 | $132.26 |
| 4 days before | -1.27% |
| 4 days after | 7.95% |
| On release day | -0.498% |
| Change in period | 6.58% |
| Release date | Apr 11, 2025 |
| Price on release | $119.66 |
| EPS estimate | - |
| EPS actual | - |
| Date | Price |
|---|---|
| Apr 07, 2025 | $104.26 |
| Apr 08, 2025 | $112.06 |
| Apr 09, 2025 | $119.54 |
| Apr 10, 2025 | $112.83 |
| Apr 11, 2025 | $119.66 |
| Apr 14, 2025 | $115.99 |
| Apr 15, 2025 | $117.64 |
| Apr 16, 2025 | $117.44 |
| Apr 17, 2025 | $115.44 |
| 4 days before | 14.77% |
| 4 days after | -3.53% |
| On release day | -3.07% |
| Change in period | 10.72% |
| Release date | Jun 30, 2025 |
| Price on release | $129.80 |
| EPS estimate | $2.26 |
| EPS actual | $1.86 |
| EPS surprise | -17.70% |
| Date | Price |
|---|---|
| Jun 24, 2025 | $126.50 |
| Jun 25, 2025 | $126.77 |
| Jun 26, 2025 | $126.30 |
| Jun 27, 2025 | $132.90 |
| Jun 30, 2025 | $129.80 |
| Jul 01, 2025 | $129.77 |
| Jul 02, 2025 | $133.99 |
| Jul 03, 2025 | $132.26 |
| Jul 07, 2025 | $133.19 |
| 4 days before | 2.61% |
| 4 days after | 2.61% |
| On release day | -0.0231% |
| Change in period | 5.29% |
| Release date | Apr 29, 2026 |
| Price on release | $110.36 |
| EPS estimate | $1.77 |
| EPS actual | $1.67 |
| EPS surprise | -5.65% |
| Date | Price |
|---|---|
| Apr 23, 2026 | $114.28 |
| Apr 24, 2026 | $107.76 |
| Apr 27, 2026 | $107.76 |
| Apr 28, 2026 | $106.94 |
| Apr 29, 2026 | $110.36 |
| Apr 30, 2026 | $106.92 |
| May 01, 2026 | $106.92 |
| May 04, 2026 | $105.76 |
| May 05, 2026 | $108.59 |
| 4 days before | -3.43% |
| 4 days after | -1.60% |
| On release day | -3.12% |
| Change in period | -4.98% |
Straumann Holding AG Earnings Call Transcript Summary of Q4 2025
Key investor points: Straumann reported FY2025 revenue of CHF 2.6 billion (organic growth 8.9%; reported +4.1% FX drag ~CHF 100m). Core gross margin was 70.1% and core EBIT margin 25.2% (26.5% at constant 2024 FX), delivering core net income CHF 478m and free cash flow CHF 290m despite one of the group's largest investment years (CapEx CHF 223m). Operational highlights: record product launches (notably iEXCEL with >1 million implants sold), strong adoption of the SIRIOS X3 scanner and rapid growth of the Straumann AXS digital platform (15,000+ active users in 18 months). Regional performance: strong EMEA (>11% organic), improving North America (late-year acceleration), APAC solid outside China, China weakened in H2 due to VBP-related patient flow and distributor destocking, and Latin America very strong (~18% organic). Orthodontics: ClearCorrect production transition to Smartee underway (EMEA/APAC) with product enhancements planned (scalloped trimline, mandibular repositioning devices) to drive scale and margin improvement. Strategy reiteration: “perform and transform” playbook — maintain leadership in implants/regenerative while scaling clear aligners, digital equipment and chairside prosthetics (printer + materials partnership). Capital allocation: Board proposes dividend CHF 1.00/share (+5%). Outlook 2026: expect high single-digit organic revenue growth and core EBIT margin expansion of 30–60 bps at constant 2025 FX; lower CapEx and improved free cash flow conversion expected as major factory ramp-ups complete. Risks/puts to watch: FX volatility, U.S. tariffs (~CHF 20m P&L impact similar to 2025), timing/impact of China VBP and residual distributor destocking, and transition costs in orthodontics in H1 2026 with larger benefits back-end year.
